8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Mar 2, 2026·SEC
UroGen Pharma Ltd.(URGN)Earnings, Financials & Key Ratios
URGN•NASDAQ
Price updated Jun 19, 2026
AboutUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Show more
- Revenue$110M+21.4%
- EBITDA-$122M-27.0%
- Net Income-$153M-21.0%
- EPS (Diluted)-3.19-7.8%
- Gross Margin88.66%-1.7%
- EBITDA Margin-111.54%-4.5%
- Operating Margin-113.73%-6.2%
- Net Margin-139.81%+0.4%
URGN Key Insights
UroGen Pharma Ltd. (URGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Strong 5Y sales CAGR of 56.2%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 12.2% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when URGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
URGN Price & Volume
UroGen Pharma Ltd. (URGN) stock price & volume — 10-year historical chart
Loading chart...
URGN Growth Metrics
UroGen Pharma Ltd. (URGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years56.22%
3 Years19.49%
TTM52.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM13.52%
Return on Capital
10 Years-64.07%
5 Years-66.59%
3 Years-54.7%
Last Year-63.41%
URGN Recent Earnings
UroGen Pharma Ltd. (URGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.47+16.1%
$0.56
Rev
$51M+13.7%
$45M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.54-4.2%
$0.52
Rev
$38M-5.2%
$40M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.69+4.2%
$0.72
Rev
$27M-31.5%
$40M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.05-28.0%
$0.82
Rev
$24M-27.9%
$34M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.47vs $0.56+16.1% | $51Mvs $45M+13.7% |
| Q2 2026 | Mar 2, 2026 | $0.54vs $0.52-4.2% | $38Mvs $40M-5.2% |
| Q4 2025 | Nov 6, 2025 | $0.69vs $0.72+4.2% | $27Mvs $40M-31.5% |
| Q3 2025 | Aug 7, 2025 | $1.05vs $0.82-28.0% | $24Mvs $34M-27.9% |
Based on last 12 quarters of dataView full earnings history →
URGN Peer Comparison
UroGen Pharma Ltd. (URGN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PCVX | 7.43B | 51.44 | -9.14 | -32.51% | 0.09 | |||
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 1.29B | 31.85 | 26.76 | 27.37% | 6.29% | 30.81% | 2.67 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ANIP | 1.81B | 79.49 | 23.94 | 43.78% | 9.71% | 17.32% | 0.60 | |
 CRVS | 1B | 11.91 | -22.47 | -38.92% | 0.02 |
Compare URGN vs Peers
UroGen Pharma Ltd. (URGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
URGN Income Statement
UroGen Pharma Ltd. (URGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 8.16M | 1.13M | 18K | 11.8M | 48.04M | 64.36M | 82.71M | 90.4M | 109.79M | 140.49M |
Revenue Growth % | -53.46% | -86.17% | -98.4% | 65450% | 307.17% | 33.96% | 28.52% | 9.29% | 21.45% | 52.92% |
Cost of Goods Sold | 600K | 1.8M | 0 | 1.01M | 5.16M | 7.65M | 9.36M | 8.88M | 12.45M | 14.26M |
COGS % of Revenue | 7.35% | 159.84% | - | 8.55% | 10.73% | 11.89% | 11.32% | 9.82% | 11.34% | - |
Gross Profit | 7.56M▲ 0% | -675K▼ 108.9% | 18K▲ 102.7% | 10.79M▲ 59844.4% | 42.88M▲ 297.5% | 56.7M▲ 32.2% | 73.35M▲ 29.4% | 81.52M▲ 11.1% | 97.34M▲ 19.4% | 126.24M▲ 0% |
Gross Margin % | 92.65% | -59.84% | 100% | 91.45% | 89.27% | 88.11% | 88.68% | 90.18% | 88.66% | 89.85% |
Gross Profit Growth % | -56.82% | -108.93% | 102.67% | 59844.44% | 297.45% | 32.22% | 29.36% | 11.13% | 19.41% | - |
Operating Expenses | 27.51M | 76.5M | 109.5M | 137.53M | 135.18M | 135.74M | 138.89M | 178.3M | 222.2M | 234.45M |
OpEx % of Revenue | 337.19% | 6782.36% | 608311.11% | 1165.6% | 281.37% | 210.92% | 167.92% | 197.24% | 202.39% | - |
Selling, General & Admin | 8.81M | 39.57M | 60.2M | 90.22M | 0 | 82.84M | 93.27M | 0 | 155.1M | 171.62M |
SG&A % of Revenue | 108% | 3508.07% | 334438.89% | 764.63% | - | 128.72% | 112.77% | - | 141.27% | - |
Research & Development | 18.7M | 36.93M | 49.3M | 47.31M | 47.64M | 52.91M | 45.61M | 57.15M | 67.11M | 62.83M |
R&D % of Revenue | 229.19% | 3274.29% | 273872.22% | 400.97% | 99.17% | 82.21% | 55.15% | 63.21% | 61.12% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 87.53M | 0 | 0 | 121.15M | 0 | 0 |
Operating Income | -19.95M▲ 0% | -77.18M▼ 286.9% | -109.48M▼ 41.8% | -126.74M▼ 15.8% | -92.29M▲ 27.2% | -79.04M▲ 14.4% | -65.54M▲ 17.1% | -96.78M▼ 47.7% | -124.86M▼ 29.0% | -108.21M▲ 0% |
Operating Margin % | -244.55% | -6842.2% | -608211.11% | -1074.15% | -192.11% | -122.82% | -79.23% | -107.06% | -113.73% | -77.02% |
Operating Income Growth % | -2600% | -286.87% | -41.85% | -15.77% | 27.18% | 14.36% | 17.09% | -47.68% | -29.01% | - |
EBITDA | -19.74M | -76.76M | -108.15M | -124.69M | -91.46M | -77.22M | -63.83M | -96.45M | -122.45M | -105.65M |
EBITDA Margin % | -242.01% | -6805.23% | -600855.56% | -1056.83% | -190.38% | -119.99% | -77.17% | -106.7% | -111.54% | -75.2% |
EBITDA Growth % | -2052.82% | -288.81% | -40.89% | -15.29% | 26.65% | 15.57% | 17.34% | -51.11% | -26.96% | 1.14% |
D&A (Non-Cash Add-back) | 207K | 417K | 1.32M | 2.04M | 831K | 1.82M | 1.71M | 329K | 2.41M | 2.57M |
EBIT | -19.95M | -77.18M | -109.48M | -124.75M | -92.29M | -78.03M | -62.06M | -95.68M | -138.07M | -118.95M |
Net Interest Income | 125K | 1.87M | 4.33M | 1.63M | 365K | -7.5M | -12.07M | -3.62M | -27.88M | -33.78M |
Interest Income | 125K | 1.87M | 4.62M | 1.99M | 365K | 938K | 2.64M | 8.9M | 5.96M | 4.69M |
Interest Expense | 0 | 0 | 284K | 357K | 0 | 8.44M | 14.71M | 12.52M | 33.85M | 38.47M |
Other Income/Expense | -31K | 1.65M | 4.33M | 1.63M | -17.08M | -28.99M | -32.79M | -27.26M | -28.55M | -30.1M |
Pretax Income | -19.98M▲ 0% | -75.53M▼ 278.0% | -105.15M▼ 39.2% | -125.11M▼ 19.0% | -109.37M▲ 12.6% | -108.03M▲ 1.2% | -98.32M▲ 9.0% | -124.04M▼ 26.2% | -153.42M▼ 23.7% | -138.31M▲ 0% |
Pretax Margin % | -244.93% | -6696.1% | -584144.44% | -1060.34% | -227.66% | -167.86% | -118.87% | -137.22% | -139.74% | -98.45% |
Income Tax | 19K | 125K | 0 | 3.37M | 1.45M | 1.75M | 3.92M | 2.83M | 78K | -5.09M |
Effective Tax Rate % | -0.1% | -0.17% | 0% | -2.7% | -1.32% | -1.62% | -3.99% | -2.28% | -0.05% | 3.68% |
Net Income | -20M▲ 0% | -75.66M▼ 278.3% | -105.15M▼ 39.0% | -128.48M▼ 22.2% | -110.82M▲ 13.7% | -109.78M▲ 0.9% | -102.24M▲ 6.9% | -126.87M▼ 24.1% | -153.49M▼ 21.0% | -133.22M▲ 0% |
Net Margin % | -245.16% | -6707.18% | -584144.44% | -1088.94% | -230.67% | -170.58% | -123.61% | -140.35% | -139.81% | -94.83% |
Net Income Growth % | -930.4% | -278.28% | -38.98% | -22.2% | 13.75% | 0.94% | 6.87% | -24.09% | -20.98% | 3.76% |
Net Income (Continuing) | -20M | -75.66M | -105.15M | -128.48M | -110.82M | -109.78M | -102.24M | -126.87M | -153.49M | -133.22M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.06▲ 0% | -4.80▼ 133.0% | -4.90▼ 2.1% | -5.90▼ 20.4% | -4.96▲ 15.9% | -4.79▲ 3.4% | -3.55▲ 25.9% | -2.96▲ 16.6% | -3.19▼ 7.8% | -2.65▲ 0% |
EPS Growth % | -1187.5% | -133.01% | -2.08% | -20.41% | 15.93% | 3.43% | 25.89% | 16.62% | -7.77% | 13.52% |
EPS (Basic) | -2.06 | -4.80 | -4.90 | -5.90 | -4.96 | -4.79 | -3.55 | -2.96 | -3.19 | - |
Diluted Shares Outstanding | 9.72M | 15.75M | 20.53M | 21.78M | 22.35M | 22.81M | 28.83M | 42.88M | 48.12M | 50.18M |
Basic Shares Outstanding | 9.72M | 15.75M | 20.53M | 21.78M | 22.35M | 22.81M | 28.83M | 42.88M | 48.12M | 50.18M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
URGN Balance Sheet
UroGen Pharma Ltd. (URGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 74.47M | 102.24M | 148.63M | 115.62M | 114.39M | 128.91M | 169.19M | 276.13M | 186.02M | 237.46M |
Cash & Short-Term Investments | 73M | 101.32M | 147.08M | 102.02M | 89.14M | 99.96M | 136.97M | 236.69M | 120.46M | 141.6M |
Cash Only | 37M | 101.32M | 49.69M | 52.86M | 44.36M | 55.41M | 95M | 171.99M | 110.75M | 111.3M |
Short-Term Investments | 36M | 0 | 97.39M | 49.15M | 44.78M | 44.56M | 41.97M | 64.7M | 9.71M | 30.31M |
Accounts Receivable | 0 | 0 | 0 | 7.05M | 11.72M | 12.7M | 15.44M | 20.3M | 33.08M | 55.41M |
Days Sales Outstanding | - | - | - | 218 | 89.02 | 72.05 | 68.15 | 81.97 | 109.98 | 83.04 |
Inventory | 316K | 0 | 0 | 1.96M | 4.83M | 4.33M | 5.67M | 9.23M | 16.46M | 20.92M |
Days Inventory Outstanding | 192.23 | - | - | 710.47 | 342 | 206.25 | 221.2 | 379.22 | 482.8 | 338.31 |
Other Current Assets | 198K | 253K | 523K | 1.23M | 1.23M | 11.91M | 11.1M | 9.92M | 16.02M | 19.53M |
Total Non-Current Assets | 1.08M | 1.32M | 53.75M | 6.39M | 5.36M | 6.71M | 9.13M | 9.58M | 14.43M | 16.23M |
Property, Plant & Equipment | 805K | 948K | 4.71M | 4.2M | 3.15M | 3.75M | 2.36M | 3.79M | 9.09M | 8.56M |
Fixed Asset Turnover | 10.13x | 1.19x | 0.00x | 2.81x | 15.27x | 17.17x | 35.05x | 23.86x | 12.07x | 16.99x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 29K | 51K | 48.55M | 1.89M | 675K | 0 | 4.5M | 5.02M | 0 | 5.37M |
Other Non-Current Assets | 244K | 317K | 487K | 289K | 1.53M | 2.96M | 2.26M | 765K | 5.34M | 7.49M |
Total Assets | 75.55M▲ 0% | 103.56M▲ 37.1% | 202.39M▲ 95.4% | 122M▼ 39.7% | 119.75M▼ 1.9% | 135.62M▲ 13.3% | 178.31M▲ 31.5% | 285.71M▲ 60.2% | 200.46M▼ 29.8% | 253.69M▲ 0% |
Asset Turnover | 0.11x | 0.01x | 0.00x | 0.10x | 0.40x | 0.47x | 0.46x | 0.32x | 0.55x | 0.66x |
Asset Growth % | 227.68% | 37.07% | 95.43% | -39.72% | -1.85% | 13.26% | 31.48% | 60.23% | -29.84% | -92.05% |
Total Current Liabilities | 7.04M | 13.46M | 19.48M | 21.44M | 22.38M | 23.92M | 31.21M | 45.95M | 46.42M | 50.63M |
Accounts Payable | 2.84M | 4.27M | 4.69M | 3.27M | 5.79M | 5.53M | 6.51M | 10.93M | 12.14M | 17.21M |
Days Payables Outstanding | 1.73K | 864.83 | - | 1.18K | 409.52 | 263.57 | 253.99 | 449.25 | 355.91 | 340.45 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.92M |
Deferred Revenue (Current) | 650K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.28M |
Other Current Liabilities | -1.6M | 0 | 1.58M | 11.41M | 10.28M | 11.53M | 14.67M | 18.52M | 34.28M | 13.39M |
Current Ratio | 10.59x | 7.59x | 7.63x | 5.39x | 5.11x | 5.39x | 5.42x | 6.01x | 4.01x | 4.69x |
Quick Ratio | 10.54x | 7.59x | 7.63x | 5.30x | 4.90x | 5.21x | 5.24x | 5.81x | 3.65x | 4.28x |
Cash Conversion Cycle | - | - | - | -254.8 | 21.5 | 14.73 | 35.36 | 11.94 | 236.87 | 80.89 |
Total Non-Current Liabilities | 0 | 0 | 2.6M | 4.21M | 88.95M | 201.06M | 212.31M | 248.56M | 259.51M | 327.31M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 97.54M | 98.55M | 121.73M | 122.21M | 189.53M |
Capital Lease Obligations | 0 | 0 | 2.6M | 1.5M | 398K | 1.59M | 844K | 1.65M | 6.12M | 21.42M |
Deferred Tax Liabilities | 0 | 0 | 0 | 2.72M | 2.84M | 3.02M | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 85.71M | 98.92M | 112.92M | 125.18M | 131.18M | 132.13M |
Total Liabilities | 7.04M | 13.46M | 22.09M | 25.65M | 111.33M | 224.98M | 243.52M | 294.51M | 305.93M | 377.94M |
Total Debt | 0 | 0 | 2.6M | 1.5M | 398K | 99.12M | 99.39M | 123.39M | 128.33M | 197.09M |
Net Debt | -37M | -101.32M | -47.08M | -51.37M | -43.96M | 43.72M | 4.39M | -48.6M | 17.59M | 85.8M |
Debt / Equity | - | - | 0.01x | 0.02x | 0.05x | - | - | - | - | -1.59x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.87x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.81x |
Interest Coverage | - | - | -385.49x | -349.45x | - | -9.25x | -4.22x | -7.64x | -4.08x | -3.09x |
Total Equity | 68.52M▲ 0% | 90.09M▲ 31.5% | 180.3M▲ 100.1% | 96.36M▼ 46.6% | 8.41M▼ 91.3% | -89.36M▼ 1162.2% | -65.21M▲ 27.0% | -8.8M▲ 86.5% | -105.47M▼ 1098.2% | -124.25M▲ 0% |
Equity Growth % | 320.16% | 31.5% | 100.13% | -46.56% | -91.27% | -1162.18% | 27.02% | 86.5% | -1098.16% | -2225.96% |
Book Value per Share | 7.05 | 5.72 | 8.78 | 4.42 | 0.38 | -3.92 | -2.26 | -0.21 | -2.19 | -2.48 |
Total Shareholders' Equity | 68.52M | 90.09M | 180.3M | 96.36M | 8.41M | -89.36M | -65.21M | -8.8M | -105.47M | -124.25M |
Common Stock | 37K | 44K | 57K | 60K | 61K | 63K | 89K | 115K | 133K | 134K |
Retained Earnings | -47.21M | -122.87M | -228.02M | -356.5M | -467.32M | -577.1M | -679.35M | -806.22M | -959.72M | -983.29M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -577K | -747K | 276K | 271K | -25K | -107K | 12K | 56K | 19K | 8K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
URGN Cash Flow Statement
UroGen Pharma Ltd. (URGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.57M | -37.33M | -71.02M | -105.89M | -84.89M | -87.56M | -76.38M | -96.77M | -162.44M | -165.74M |
Operating CF Margin % | -117.32% | -3309.75% | -394538.89% | -897.41% | -176.7% | -136.05% | -92.34% | -107.04% | -147.96% | - |
Operating CF Growth % | -328.48% | -290.07% | -90.22% | -49.1% | 19.83% | -3.14% | 12.77% | -26.7% | -67.87% | -309.74% |
Net Income | -20M | -75.66M | -105.15M | -128.48M | -110.82M | -109.78M | -102.24M | -126.87M | -153.49M | -133.22M |
Depreciation & Amortization | 207K | 417K | 1.32M | 2.04M | 1.77M | 1.82M | 1.71M | 1.19M | 2.41M | 2.57M |
Stock-Based Compensation | 6.3M | 30.64M | 29.97M | 28.02M | 23.11M | 10.58M | 9.34M | 13.11M | 11.96M | 8.89M |
Deferred Taxes | 0 | 0 | -572K | 439K | 15.32M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 165K | 100K | -910K | -1.54M | -1.18M | 16.13M | 11.48M | 10.88M | 4.59M | 9.23M |
Working Capital Changes | 3.76M | 7.16M | 4.32M | -6.37M | -13.11M | -6.31M | 3.34M | 4.93M | -27.91M | -53.19M |
Change in Receivables | 83K | 3.29M | 0 | -7.05M | -4.67M | -987K | -2.74M | -4.86M | -12.78M | -36.58M |
Change in Inventory | -211K | 316K | 0 | -1.96M | -2.87M | -362K | -1.35M | -3.55M | -7.24M | -13.81M |
Change in Payables | 2.53M | 4.21M | 2.93M | -1.25M | 2M | 281K | 4.16M | 10.89M | 286K | 9.25M |
Cash from Investing | -36.38M | 35.29M | -145.59M | 93.24M | 4.07M | 1.06M | -953K | -20.61M | 61.56M | 66.83M |
Capital Expenditures | -271K | -560K | -325K | -1.22M | -752K | -254K | -194K | -295K | -289K | -299K |
CapEx % of Revenue | 3.32% | 49.65% | 1805.56% | 10.3% | 1.57% | 0.39% | 0.23% | 0.33% | 0.26% | 0.21% |
Acquisitions | 0 | 0 | 0 | -94.45M | -4.82M | -1.31M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -105K | -54K | -172K | 94.45M | 4.82M | 1.31M | 0 | 0 | 0 | 0 |
Cash from Financing | 61.59M | 66.42M | 165.25M | 16.53M | 72.32M | 97.13M | 116.93M | 194.62M | 39.92M | 105.09M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 95.78M | 0 | 24.49M | -1.85M | -2.29M |
Equity Issued (Net) | 60.84M | 64.23M | 161.66M | 15.85M | -83K | 1.35M | 67.36M | 151.17M | 41.77M | 145K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 744K | 2.19M | 3.59M | 674K | 72.4M | 0 | 49.57M | 18.96M | 0 | 107.23M |
Net Change in Cash | 15.64M▲ 0% | 64.37M▲ 311.7% | -51.36M▼ 179.8% | 3.88M▲ 107.6% | -8.5M▼ 319.2% | 10.63M▲ 225.1% | 39.6M▲ 272.4% | 77.24M▲ 95.0% | -60.97M▼ 178.9% | 6.19M▲ 0% |
Free Cash Flow | -9.84M▲ 0% | -37.89M▼ 285.0% | -71.34M▼ 88.3% | -107.1M▼ 50.1% | -85.64M▲ 20.0% | -87.81M▼ 2.5% | -76.57M▲ 12.8% | -97.06M▼ 26.8% | -162.73M▼ 67.7% | -166.03M▲ 0% |
FCF Margin % | -120.64% | -3359.4% | -396344.44% | -907.71% | -178.27% | -136.45% | -92.57% | -107.37% | -148.22% | -118.18% |
FCF Growth % | -381.68% | -285.02% | -88.27% | -50.12% | 20.03% | -2.53% | 12.8% | -26.76% | -67.66% | -54.6% |
FCF per Share | -1.01 | -2.41 | -3.48 | -4.92 | -3.83 | -3.85 | -2.66 | -2.26 | -3.38 | -3.31 |
FCF Conversion (FCF/Net Income) | 0.48x | 0.49x | 0.68x | 0.82x | 0.77x | 0.80x | 0.75x | 0.76x | 1.06x | 1.25x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
URGN Key Ratios
UroGen Pharma Ltd. (URGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -47.16% | -95.4% | -77.77% | -92.88% | -211.55% | - | - | - | - | 121.52% |
Return on Invested Capital (ROIC) | -113.09% | -570.52% | -134.61% | -106.68% | -1466.66% | - | - | - | - | 124.54% |
Gross Margin | 92.65% | -59.84% | 100% | 91.45% | 89.27% | 88.11% | 88.68% | 90.18% | 88.66% | 89.85% |
Net Margin | -245.16% | -6707.18% | -584144.44% | -1088.94% | -230.67% | -170.58% | -123.61% | -140.35% | -139.81% | -94.83% |
Debt / Equity | - | - | 0.01x | 0.02x | 0.05x | - | - | - | - | -1.59x |
Interest Coverage | - | - | -385.49x | -349.45x | - | -9.25x | -4.22x | -7.64x | -4.08x | -3.09x |
FCF Conversion | 0.48x | 0.49x | 0.68x | 0.82x | 0.77x | 0.80x | 0.75x | 0.76x | 1.06x | 1.25x |
Revenue Growth | -53.46% | -86.17% | -98.4% | 65450% | 307.17% | 33.96% | 28.52% | 9.29% | 21.45% | 52.92% |
Related:URGN Dividend History·URGN Revenue History·URGN Price History·URGN P/E History·URGN Financial Ratios·URGN Institutional Holders
URGN SEC Filings & Documents
UroGen Pharma Ltd. (URGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
URGN Frequently Asked Questions
UroGen Pharma Ltd. (URGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
UroGen Pharma Ltd. (URGN) reported $140.5M in revenue for fiscal year 2025.
UroGen Pharma Ltd. (URGN) grew revenue by 21.4% over the past year. This is strong growth.
UroGen Pharma Ltd. (URGN) reported a net loss of $133.2M for fiscal year 2025.
Dividend & Returns
UroGen Pharma Ltd. (URGN) had negative free cash flow of $166.0M in fiscal year 2025, likely due to heavy capital investments.